Tema Etfs LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Tema Etfs LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 30,846 shares of the biopharmaceutical company's stock, valued at approximately $2,849,000. Gilead Sciences accounts for about 1.2% of Tema Etfs LLC's portfolio, making the stock its 28th largest holding.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. FMR LLC boosted its position in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares during the period. Wellington Management Group LLP boosted its position in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after acquiring an additional 1,058,331 shares during the period. Geode Capital Management LLC boosted its position in Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after acquiring an additional 749,047 shares during the period. Norges Bank acquired a new position in Gilead Sciences during the 4th quarter worth $1,789,254,000. Finally, Northern Trust Corp boosted its position in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after acquiring an additional 2,458,954 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the sale, the chief financial officer now owns 165,674 shares in the company, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 22,929 shares of company stock valued at $2,634,220. Company insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of a number of research analyst reports. The Goldman Sachs Group upped their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research report on Thursday, February 13th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Royal Bank of Canada upped their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $2.95 during mid-day trading on Tuesday, hitting $109.11. 10,711,437 shares of the company's stock traded hands, compared to its average volume of 7,704,931. The firm has a 50 day moving average of $105.51 and a two-hundred day moving average of $100.02. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The firm has a market capitalization of $135.73 billion, a price-to-earnings ratio of 294.89, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the company earned ($1.32) earnings per share. The company's revenue for the quarter was down .3% compared to the same quarter last year. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.90%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.